J&J’s Ethicon wins FDA breakthrough nod for microwave ablation tech

Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon announced that it received FDA breakthrough device designation for its microwave ablation technology.

The transbronchial microwave ablation technology, which is currently under development, utilizes robotic-assisted bronchoscopy. Johnson & Johnson’s acquisitions of NeuWave Medical and Auris Health allowed the company to bring the robotic surgical and microwave ablation technology together to develop the new breakthrough device, according to a news release.

Ethicon’s NeuWave microwave ablation system treats soft tissue lesions, having already performed more than 45,000 procedures to date. Meanwhile, the Monarch platform — the first robotic-assisted bronchoscopy system introduced in the U.S. — offers reach into the periphery of the lung with continuous real-time vision, precision and control.

“Through our commitment to transform patients’ lives, Johnson & Johnson is advancing innovativ…

Read more
  • 0